EVE Health Group to Host Investor Webinar on 12 November 2026 with CEO Ben Rohr

Mukul

06 November 2026 11:23 AM AEDT

EVE Health Group to Host Investor Webinar on 12 November 2026 with CEO Ben Rohr

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

EVE Health Group (ASX:EVE) has announced it will host an investor webinar on Thursday, 12 November 2026 at 11.30am AEDT, to be presented by Chief Executive Officer Ben Rohr, with a question-and-answer session to follow.

Key Points

EVE Health Group will host an investor webinar on 12 November 2026 at 11.30am AEDT (8.30am AWST)
The webinar will be presented by Chief Executive Officer Ben Rohr
Participants will have the opportunity to ask questions following the presentation
Registration in advance is required; participants will receive a confirmation email with joining details

Investor Webinar Details and Format

EVE Health Group disclosed on 6 November 2026 that it will host an investor webinar to provide shareholders with a business update. The session is scheduled for Thursday, 12 November 2026, at 11.30am Australian Eastern Daylight Time, which corresponds to 8.30am Australian Western Standard Time. The webinar will be presented by Chief Executive Officer Ben Rohr and will be followed by an opportunity for participants to submit questions. The company said participants are required to register in advance via the designated webinar link, after which a confirmation email containing joining information will be sent.

Company Overview and Lead Assets

According to the filing, EVE Health Group is an Australian life sciences company focused on developing and commercialising pharmaceutical solutions in therapeutic areas. The company's lead assets include Dyspro®, described as a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. The filing states both products leverage the company's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes.

Digital Health Platform and Patient Engagement Pathways

The filing states EVE Health Group is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement, and prescribing pathways. The company operates dedicated information platforms, including ReclaimMyCycle.com for women's health and StiffIssue.com for men's health, which the filing describes as providing condition-focused education, reducing stigma, and supporting earlier engagement with appropriate care. These platforms, according to the filing, integrate with telehealth and pharmacy fulfilment networks to enable access to treatment within a regulated healthcare framework.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.